Literature DB >> 7925778

Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.

K Okuda1, U Matulonis, R Salgia, Y Kanakura, B Druker, J D Griffin.   

Abstract

The proliferation of normal hematopoietic cells is strictly factor dependent, while leukemic cell lines and primary leukemic cells are frequently factor independent. Although autocrine growth stimulation of human leukemias is occasionally observed in vitro, it is possible that mutations of signal-transduction or cell-cycle control genes may also be important in the development of factor independence. We have previously shown that the proto-oncogene Raf-1, a 70-kd serine/threonine protein kinase, is rapidly phosphorylated and activated by hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and Steel factor and is likely to be an important intermediate in mitogenic signal transduction pathways in hematopoietic cells. In an effort to better understand the possible role of abnormal signal transduction in the development of factor independence, we compared the state of phosphorylation and associated kinase activity of Raf-1 between a series of factor-dependent human and murine-myeloid normal cells or cell lines and a series of factor-independent myeloid cell lines. In factor-dependent myeloid cells (normal neutrophils; monocytes; and the cell lines MO7, 32Dc13, and FDC-P1), Raf-1 phosphorylation and associated kinase activity was strictly regulated by the supply of growth factor. In contrast, each of eight factor-independent leukemic cell lines examined, HL-60, KG-1, K562, U937, JOSK-S, JOSK-M, JOSK-K, and JOSK-I, expressed hyperphosphorylated Raf-1 with increased Raf-1 associated kinase activity in the absence of growth factor addition. To further explore the relationship of Raf-1 to factor-independent growth, factor-independent sublines were derived from two factor-dependent cell lines, MO7 and FDC-P1, by culture in CSF-deprived medium. Also, several factor-independent sublines were derived by transfection of a cDNA encoding p210BCR/ABL into three different cell lines: MO7, 32Dc13, and FDC-P1. In each case, the new sublines expressed constitutively hyperphosphorylated and activated Raf-1. The correlation of hyperphosphorylation of Raf-1 with factor independence was also observed with primary acute myeloblastic leukemia cells. The rate of "spontaneous" proliferation of primary acute myeloblastic leukemia (AML) cells in vitro correlated with the extent of Raf-1 phosphorylation. These results suggest that the evolution of myeloid leukemic cells to factor independence is associated with phosphorylation and activation of Raf-1, implicating Raf-1 and signal transduction pathways which activate RAf-1 in this process.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925778

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

Authors:  M S Neshat; A B Raitano; H G Wang; J C Reed; C L Sawyers
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  The Cancer Drug Dasatinib Increases PGC-1α in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice.

Authors:  Lykke Sylow; Jonathan Z Long; Isha A Lokurkar; Xing Zeng; Erik A Richter; Bruce M Spiegelman
Journal:  Endocrinology       Date:  2016-09-02       Impact factor: 4.736

4.  Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Authors:  A Megan Cornelison; Hagop Kantarjian; Jorge Cortes; Elias Jabbour
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-28

Review 5.  Selecting the best frontline treatment in chronic myeloid leukemia.

Authors:  Musa Yilmaz; Yasmin Abaza; Elias Jabbour
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

6.  Critical prosurvival roles for C/EBP beta and insulin-like growth factor I in macrophage tumor cells.

Authors:  Jennifer Wessells; Shoshana Yakar; Peter F Johnson
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

Review 7.  Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.

Authors:  Elias Jabbour; Jorge Cortes; Farhad Ravandi; Susan O'Brien; Hagop Kantarjian
Journal:  Semin Hematol       Date:  2013-10-03       Impact factor: 3.851

8.  Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate.

Authors:  Jianjun Xie; Andre Larochelle; Irina Maric; Marion Faulhaber; Robert E Donahue; Cynthia E Dunbar
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

Review 9.  Current status and novel strategy of CML.

Authors:  Kiyomi Morita; Koji Sasaki
Journal:  Int J Hematol       Date:  2021-03-29       Impact factor: 2.490

Review 10.  Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation.

Authors:  Hui Mu; Xiaojian Zhu; Hui Jia; Lu Zhou; Hong Liu
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.